Evotec (NASDAQ:EVO) Shares Down 3.2% - What's Next?

Evotec AG (NASDAQ:EVO - Get Free Report) fell 3.2% on Thursday . The stock traded as low as $4.23 and last traded at $4.20. 17,791 shares were traded during mid-day trading, a decline of 87% from the average session volume of 135,322 shares. The stock had previously closed at $4.34.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada reissued an "outperform" rating on shares of Evotec in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.93.

Evotec Stock Down 3.3%

The company's fifty day simple moving average is $4.14 and its 200 day simple moving average is $4.05. The company has a quick ratio of 1.93, a current ratio of 2.03 and a debt-to-equity ratio of 0.46.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. DCF Advisers LLC grew its stake in Evotec by 227.0% in the first quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after purchasing an additional 521,708 shares during the period. ABC Arbitrage SA bought a new stake in shares of Evotec during the 1st quarter valued at $260,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec in the 4th quarter worth about $166,000. CSS LLC IL bought a new position in shares of Evotec in the 4th quarter worth about $50,000. Finally, Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. Institutional investors own 5.81% of the company's stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.